Skip to main content
Skip to main content
Home
Company
About Us
Executive Team
Board of Directors
Scientific & Clinical Advisors
Partners
Pipeline
Technology
EQ504
EQ302
Publications
Presentations
Investors
Investor Overview
Stock Information
Stock Chart
Analyst Coverage
Press Releases
Events & Presentations
Email Alerts & Contacts
SEC Filings
Corporate Governance
Governance Documents
Committee Composition
Investor FAQs
Careers
Contact Us
Search query
Presentation Details
Back
Antigenic Modulation of CD6 by Itolizumab is a Novel Mechanism for Effector T Cell Inhibition<span>Dalena Chu. et. al.</span><span>American Society of Hematology (ASH)</span><span>2021</span>
12/11/2021
Download this Press Release
PDF Format (opens in new window)
width="640" height="360" frameborder="0" allow="autoplay; fullscreen" allowfullscreen="">
Dalena Chu. et. al.
Conference:
American Society of Hematology (ASH)
Year:
2021
